Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor

Journal of Medicinal Chemistry

Volumn 40, Issue 5, 1997, Pages 659-667

  Sheskin, Tzviel ^a   Hanuš, Lumir ^a   Slager, Joram ^a   Vogel, Zvi ^b   Mechoulam, Raphael ^a,c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; CANNABINOID RECEPTOR;

ALKYLATION; ANIMAL TISSUE; ARTICLE; DRUG BINDING; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HYDROXYLATION; HYPOPHYSIS ADRENAL SYSTEM; NONHUMAN; RAT; STRUCTURE ANALYSIS;

AMIDES; ANIMALS; ARACHIDONIC ACIDS; BRAIN; ETHANOLAMINES; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; POLYUNSATURATED ALKAMIDES; PROTEIN BINDING; RATS; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; STRUCTURE-ACTIVITY RELATIONSHIP; SYNAPTOSOMES;

EID: 0031051583     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960752x     Document Type: Article

References (41)

1. Devane, W. A.; Hanuš, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258, 1946-1949.
2. (a) Hanuš, L.; Gopher, A.; Almog, S.; Mechoulam, R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. 1993, 36, 3032-3034.
3. (b) Barg, J.; Fride, E.; Hanuš, L.; Levy, R.; Matus-Leibovitch, N.; Heldman, E.; Bayewitch, M.; Mechoulam, R.; Vogel, Z. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Eur. J. Pharmacol. 1995, 287, 145-152.
4. (a) Fride, E.; Mechoulam, R. The Unpaved Road to the Endogenous Brain Cannabinoid Ligands, the Anandamides. In Cannabinoid Receptors; Pertwee, R., Ed.; Academic Press: London, 1995; pp 233-258.
5. (b) Mechoulam, R.; Hanuš, L.; Martin, B. R. Search for endogenous ligands of the cannabinoid receptor. Biochem. Pharm. 1994, 48, 1537-1544.
6. Di Marzo, V.; De Petrocellis, L.; Bisogno, T.; Maurelli, S. Pharmacology and physiology of the endogenous cannabimimetic mediator anandamide. J. Drug Dev. Clin. Pract. 1995, 7, 199-219.
7. In view of the existence of numerous related unsaturated fatty acid ethanolamides which bind to the cannabinoid receptor, we suggest to name this group of compounds "anandamides" with each individual member identified with the parent fatty acid indicated (in parentheses) using the generally accepted fatty acid shorthand designation. Thus the anandamide derived from arachidonic acid will be anandamide (20:4, n-6). According to this proposed nomenclature dihomo-γ-linolenylethanolamide (2) will be anandamide (20:3, n-6) and docosatetraenylethanolamide (3) will be anandamide (22:4, n-6). When only ther term "anandamide" is used, it refers to arachidonoylethanolamide (1).
8. Gaoni, Y.; Mechoulam, R. Isolation, structure and partial synthesis of an active constituent of hashish. J. Amer. Chem. Soc., 1964, 86, 1646.
9. Vogel, Z.; Barg, J.; Levy, R.; Saya, D.; Heldman, E.; Mechoulam, R. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J. Neurochem. 1993, 61, 325-355.
10. Weidenfeld, J.; Feldman, S.; Mechoulam, R. The effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology 1994, 59, 110-112.
11. Fride, E.; Mechoulam, R. Pharmacological activity of the cannabinoid agonist anandamide, a brain constituent. Eur. J. Pharmacol. 1993, 231, 313-314. Smith, P. B.; Compton, D. R.; Welch, S. P.; Razdan, R. K.; Mechoulam, R.; Martin, B. R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 1994, 270, 219-227.
12. Fride, E.; Mechoulam, R. Pharmacological activity of the cannabinoid agonist anandamide, a brain constituent. Eur. J. Pharmacol. 1993, 231, 313-314. Smith, P. B.; Compton, D. R.; Welch, S. P.; Razdan, R. K.; Mechoulam, R.; Martin, B. R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 1994, 270, 219-227.
13. Mallet, P. E.; Beninger, R. J. The endogenous cannabinoid receptor agonist anandamide impairs memory in rats. Behav. Pharmacol. 1996, 7, 276-284.
14. Varga, K.; Lake, K.; Martin, B. R.; Kunos, G. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur. J. Pharmacol. 1995, 278, 279-283.
15. Shohami, E.; Weidenfeld, J.; Ovadia, H.; Vogel, Z.; Hanuš, L.; Fride, E.; Breuer, A.; Ben-Shabat, S.; Sheskin, T.; Mechoulam, R. Endogenous and synthetic cannabinoids: recent advances. CNS Drug Rev., in press.
16. Schmid, P. C.; Krebsbach, R. J.; Perry, S. R.; Dettmer, T. M.; Maasson, J. L.; Schmid, H. H. O. Occurence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett. 1995, 375, 117-120.
17. Kempe, K.; Hsu, F.-F.; Bohrer, A.; Turk, J. Isotope dilution mass spectrometric measurements indicate that arachidonylethanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or is absent from tresh tissue. J. Biol. Chem. 1996, 17287-17295.
18. (a) Sugiura, T.; Kondo, S.; Sukagawa, A.; Tonegawa, T.; Nakane, S.; Yamashita, A.; Ishima, Y.; Waku, K. Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes - Comparison with synthesis from free arachidonic acid and ethanolamine. Eur. J. Biochem. 1996, 240, 53-60.
19. (b) Sugiura, T.; Kondo, S.; Sukagawa, A.; Tonegawa, T.; Nakane, S.; Yamashita, A.; Waku, K. Enzymatic synthesis of anandamide, an endogenous cannabinoid receptor ligand, through N-acylphosphatidyl ethanolamine pathway in testis: Involvement of CA2+dependent transacylase and phosphodiesterase activities. Biochem. Biophys. Res. Commun. 1996, 218, 113-117.
20. Lapidot, Y.; Rappaport, S.; Wolman, Y. Use of esters of N-hydroxysuccinimide in the synthesis of N-acylamino acids. J. Lipid Res. 1967, 8, 142-145.
21. Felder, C. C.; Briley, E. M.; Axelrod, J.; Simpson, J. T.; Mackie, K.; Devane, W. A. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned hbuman cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci., U.S.A. 1993, 90, 7656-7660.
22. Pinto, J. C.; Potie, F.; Rice, K. C.; Boring, D.; Ross Johnson, M.; Evans, D. M.; Wilken, G. H.; Cantrell, C. H.; Howlett, A. C. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol. Pharmacol. 1994, 46, 516-522.
23. Abadji, V.; Lin, S.; Taha, G.; Griffin, G.; Stevenson, A.; Pertwee, R.; Makriyannis, A. (R)-methanandamide: A chiral novel anandamide possessing higher potencty and metabolic stability. J. Med. Chem. 1994, 37, 1889-1893.
24. Adams, I. B.; Ryan, W.; Singer, M.; Razdan, R. K.; Compton, D. R.; Martin, B. R. Pharmacological and behavioral evaluation of alkylated anandamide analogs. Life Sci. 1995, 56, 2041-2048.
25. Fontana, A.; Di Marzo, V.; Cadas, H.; Piomelli, D. Analysis of anandamide, an endogenous cannabinoid substance, and of other natural N-acylethanolamines. Prostaglandins, Leukotrienes, Essent. Fatty Acids 1995, 53, 301-308.
26. Edgemond, W. S.; Campbell, W. B.; Hillard, C. J. The binding of novel phenolic derivatives of anandamide to brain cannabinoid receptors. Prostaglandins, Leukotrienes, Essent. Fatty Acids 1995, 52, 83-86.
27. Adams, I. B.; Ryan, W.; Singer, M.; Thomas, B. F.; Compton, D. R.; Razdan, R. K.; Martin, B. R. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J. Pharmacol. Exp. Ther. 1995, 273, 1172-1181.
28. Thomas, B. F.; Adams, I. B.; Mascarella, W.; Martin, B. R.; Razdan, R. K. Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore. J. Med. Chem. 1996, 39, 471-479.
29. Childers, S. R.; Sexton, T.; Roy, M. B. Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem. Pharmacol. 1994, 47, 711-715.
30. Devane, W. A.; Breuer, A.; Sheskin, T.; Järbe, T. U. C.; Eisen, M.; Mechoulam, R. A novel probe for the cannabinoid receptor. J. Med. Chem. 1992, 35, 2065-2069.
31. Smith, P. B.; Compton, D. R.; Welch, S. P.; Razdan, R. K.; Mechoulam, R.; Martin, B. R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 1994, 270, 219-227.
32. Di Marzo, V.; Fontana, A.; Cadas, H.; Schinelli, S.; Cimino, G.; Schwartz, J. C.; Piomelli, D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994, 372, 686-691. Schmid, H. H. O.; Schmid, P. C.; Natarajan, V. The N-acylation-phosphodiesterase pathway and cell signalling. Chem. Phys. Lipids 1996, 80, 133-142.
33. Di Marzo, V.; Fontana, A.; Cadas, H.; Schinelli, S.; Cimino, G.; Schwartz, J. C.; Piomelli, D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994, 372, 686-691. Schmid, H. H. O.; Schmid, P. C.; Natarajan, V. The N-acylation-phosphodiesterase pathway and cell signalling. Chem. Phys. Lipids 1996, 80, 133-142.
34. Schmid, H. H. O.; Schmid, P. C.; Natarajan, V. N-acylated glycerophospholipids and their derivatives. Progr. Lipid Res. 1990, 29, 1-43.
35. Corey, E. J.; Cashman, J. R.; Kantner, S. S.; Wright, S. W. Rationally designed potent competitive inhibitors of leukotriene biosynthesis. J. Am. Chem. Soc. 1984, 106, 1503-1504.
36. Facci, L.; Dal-Toso, R.; Romanello, S.; Buriani, A.; Skaper, S. D.; Leon, A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 3376-3380.
37. Cravatt, B. F.; Prospero-Garcia, O.; Siuzdak, G.; Gilula, N. B.; Henniksen, S. J.; Boger, D. L.; Lerner, R. A. Chemical characterization of a family of brain lipids that induce sleep. Science 1995, 268, 1506-1509.
38. Downing, D. T.; Ahern, D. G.; Bachta, M. Enzyme inhibition by acetylenic compounds. Biochem. Biophys. Res. Commun. 1970, 40, 218-223.
39. Deutsch, D. G.; Chin, S. A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 1993, 46, 791-796.
40. Shinitzky, M.; Haimovitz, R. Chiral surfaces in micelles of enantiomeric N-palmitoyl and N-stearoylserine. J. Am. Chem. Soc. 1993, 115, 12545-12549.
41. 9-Tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J. Biol. Chem. 1996, 271, 9902-9905.